Ross Weinreb

Stock Analyst at Goldman Sachs

(n/a)
# 4,733
Out of 5,051 analysts
3
Total ratings
n/a
Success rate
-45.51%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Ross Weinreb

Relmada Therapeutics
Mar 24, 2022
Maintains: Buy
Price Target: $69$53
Current: $2.51
Upside: +2,011.55%